RetinaCME

This activity is expired and is no longer available for CME credit.

EXPERT INTERVIEWCME

COMPLETE Study Results on the Systemic Complement Inhibitor Eculizumab In AMD Patients With Drusen

Author(s)/Faculty: Philip J. Rosenfeld, MD, PhD
Release Date: 5/11/2012Expiration Date: 5/10/2014
Credit Type: CME / ParticipationNumber of Credits: 0
Content Type: Provider:
The COMPLETE Study is the first use of systemic complement inhibition for the treatment of dry AMD, and systemic complement inhibition with eculizumab was well tolerated through 6 months. The 6-month outcome data are currently being analyzed and will be presented...